http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE) Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
-
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
-
Pfizer (PFE) Announces U.S. FDA Approves its XELJANZ for Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
-
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
-
Pfizer Declares Fourth-Quarter 2020 Dividend
-
Pfizer (PFE) Reports FDA Acceptance of Supplemental New Drug Application for XALKORI (crizotinib)
-
FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma
-
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
-
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts
-
Pfizer (PFE), Merck (MRK) Biopharmaceutical Business, EMD Serono, Reports Publication of BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results
-
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
-
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas
-
Mylan (MYL), Pfizer Inc. (PFE) Granted European Commission Approval for Proposed Combination of Mylan and Upjohn
-
Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn
-
Pfizer Hosts Virtual Investor Day
-
Pfizer (PFE), BioNTech SE (BNTX) Announce Submission to FDA to Expand Enrollment of Phase Pivotal COVID-19 Trial up to Approx. 44K Participants
-
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
-
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020
-
Pfizer (PFE) and BioNTech (BNTX) Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
-
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
-
Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19
-
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
-
Pfizer (PFE), BioNTech (BNTX) Announces Potential Supply to EU with 200M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
-
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
-
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
-
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
-
Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
-
Biopharma Leaders Unite to Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite To Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite to Stand with Science
-
Indiana University sees 'alarming' spike in COVID-19 at frat, sorority houses
-
Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020
-
Pfizer (PFE), BioNTech (BNTX) Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
-
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
-
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
-
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
-
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
-
Pfizer (PFE) Announces Agreement with Gilead (GILD) to Manufacture Remdesivir for Treatment of COVID-19
-
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
-
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
-
Pfizer (PFE) Announces LORBRENA Significantly Improves PSF in First-Line ALK-Positive Lung Cancer
-
Pfizer (PFE) and BioNTech (BNTX) to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
-
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
-
Award-Winning Television Host Meredith Vieira Joins Pfizer's Find Your MBC Voice to Help Empower People Living with Metastatic Breast Cancer to Speak Up
-
Pfizer (PFE), BioNTech (BNTX) to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
-
Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate

